reports
Lesaka and Bank Zero Merge Ambitions in Landmark Transaction
Lesaka and Bank Zero Merge Ambitions in Landmark Transaction JOHANNESBURG, June 26, 2025 (GLOBE NEWSWIRE) -- Lesaka Technologies, Inc. (Nasdaq: LSAK; JSE: LSK) (“Lesaka” or “the group”) today announced that its wholly-owned subsidiary, Lesaka Technologies Proprietary Limited, has entered into an agreement to acquire (directly and indirectly) 100% of the issued ordinary shares of Bank Zero Mutual Bank (“Bank Zero”). The acquisition consideration will be settled through a combination of newly issued shares - such that the shareholders of Bank Zero will own approximately 12% of Lesaka’s full...
- Wedbush Research
- David Nierengarten
- Dennis Pak
- Martin Fan
Psychemedics Releases 2025 Workforce Insights Report
Psychemedics Releases 2025 Workforce Insights Report Synthetic Drug Threats and Legalization Risks Shape a New Era for Workplace Safety DALLAS, June 16, 2025 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair testing for drugs of abuse, today announced the release of its second annual Workforce Insights Report, providing a comprehensive look at the evolving drug landscape and its impact on workplace safety, hiring practices, and employer risk. The 2025 Psychemedics Insights Report draws from the largest proprietary database of hair drug testing results in the industr...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Ru...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 2, 2025 (the “Grant Date”), ORIC granted a total of 39,100 non-qualified stock options and 6,500 restricted stock units to three new non-executive employees who began their employment with ORIC in May 2025. These inducement grants were granted ...
TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(...
TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., June 06, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grant of an option to purchase 75,000 shares of its common stock and restricted stock units coveri...
TELA Bio Announces European Commercial Launch of OviTex® Inguinal for ...
TELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia Repair Based on market research, inguinal hernia repair is the most common type of hernia repair MALVERN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the European launch of OviTex Inguinal Reinforced Tissue Matrix, the only reinforced tissue matrix specifically engineered for laparoscopic and robotic-assisted inguinal hernia repair. T...
- Wedbush Research
PEGA PEGASYSTEMS INC.
KURA KURA ONCOLOGY INC.
ISR ISORAY
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
SWTX SPRINGWORKS THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
ORIC ORIC PHARMACEUTICALS
SNOW SNOWFLAKE INC. CLASS A
TNGX TANGO THERAPEUTICS
GLUE INC
JANX MONTE ROSA THERAPEUTICS INC
MLTX JANUX THERAPEUTICS INC
CRBP MOONLAKE IMMUNOTHERAPEUTICS
BCAX CORBUS PHARMACEUTICALS HOLDINGS INC.
BICARA THERAPEUTICS INC.
- David Nierengarten
- Dennis Pak
- Martin Fan
- Ritika Das
- Robert Driscoll
TELA Bio Appoints Jeffrey Blizard as President
TELA Bio Appoints Jeffrey Blizard as President Company Further Strengthens Executive Leadership Team to Drive Next Phase of Growth MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Jeffrey Blizard as President of TELA Bio, effective immediately. Mr. Blizard, who has served on TELA Bio’s Board of Directors for the past year, brings deep industry experience and proven leadership to this expanded role. “...
- Wedbush Research
TSLA TESLA INC
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
CRM SALESFORCE.COM INC.
AXTI AXT INC.
CDR CD PROJEKT S.A.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
NTLA INTELLIA THERAPEUTICS INC.
ANAB ANAPTYSBIO INC.
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
MSFT MICROSOFT CORPORATION
SMCI SUPER MICRO COMPUTER
ORIC INC.
AI ORIC PHARMACEUTICALS
STX C3.AI
GFS SEAGATE TECHNOLOGY HLDGS PLC
S GLOBALFOUNDRIES INC
JANX SENTINELONE INC
PEPG JANUX THERAPEUTICS INC
DBD PEPGEN INC
DIEBOLD NIXDORF INCORPORATED
- David Nierengarten
- Dennis Pak
- Martin Fan
ORIC® Pharmaceuticals Announces $125 Million Private Placement Financi...
ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing Financing led by SR One and includes participation from new and existing investors, including Point72, Viking Global Investors, Venrock Healthcare Capital Partners, New Enterprise Associates (NEA), Nextech, Vivo Capital, and NEXTBio Capital Pro forma cash and investments expected to fund current operating plan into the second half of 2027 and through anticipated primary endpoint readout from first ORIC-944 Phase 3 registrational trial in prostate cancer SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 28, 2025 (GLOBE...
ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary ...
ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC Broad and deep PSA responses achieved, with 59% PSA50 response rate (confirmed rate of 47%, and one additional response pending confirmation) and 24% PSA90 response rate (all confirmed) in patients with mCRPC PSA responses were observed across all ORIC-944 dose levels and at comparable rates in combination with apalutamide and with darolutamide; majority of patients are still o...
Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipen...
Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee If approved, tebipenem HBr could be the first oral carbapenem antibiotic for US patients with complicated urinary tract infections (cUTIs) An estimated 2.9 million cases of cUTIs are treated annually in the US1 with many cases requiring hospitalization, contributing to over $6 billion per year in healthcare costs2Data from the PIVOT-PO trial to be part of a planned US Food and Drug Administration (FDA) filing in 2H 2025 that Spero’...
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in June: Jefferies Global Healthcare Conference – Participating in a fireside chat on Wednesday, June 4, 2025, at 12:50 p.m. ETGoldman Sachs 46th Annual Global Healthcare Conference – Participating in...
ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of O...
ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC Conference Call and Webcast on Wednesday, May 28, 2025, at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the company will present initial data from the Phase 1b trial of ORIC-944 in combination with androgen receptor i...
- David Nierengarten
- Dennis Pak
- Martin Fan
- Ritika Das
- Robert Driscoll
NVCR NOVOCURE LTD.
FATE FATE THERAPEUTICS INC
MRSN MERSANA THERAPEUTICS
ISR ISORAY
RCUS ARCUS BIOSCIENCES
REPL REPLIMUNE GROUP
SWTX SPRINGWORKS THERAPEUTICS
APRE APREA THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
ACET ADICET BIO INC
ORIC ORIC PHARMACEUTICALS
ZNTL ZENTALIS PHARMACEUTICALS
IMNM IMMUNOME
NUVB NUVATION BIO INC (A)
CGEM CULLINAN ONCOLOGY INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
FHTX FOGHORN THERAPEUTICS
GLUE MONTE ROSA THERAPEUTICS INC
JANX JANUX THERAPEUTICS INC
NUVL NUVALENT INC
ARTV ARTIVA BIOTHERAPEUTICS INC
CRBP CORBUS PHARMACEUTICALS HOLDINGS INC.
BCAX BICARA THERAPEUTICS INC.
TELA Bio to Participate in the 2025 Jefferies Global Healthcare Confer...
TELA Bio to Participate in the 2025 Jefferies Global Healthcare Conference MALVERN, Pa., May 22, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the 2025 Jefferies Global Healthcare Conference. TELA’s management is scheduled to present at the 2025 Jefferies Global Healthcare Conference at 11:05 am ET on June 5th, 2025. Interested parties can access the live and archived webcast at . About TELA Bio, Inc.TELA Bio, ...
Psychemedics Named “Most Innovative Drug Testing Company of the Year”
Psychemedics Named “Most Innovative Drug Testing Company of the Year” DALLAS, May 16, 2025 (GLOBE NEWSWIRE) -- Psychemedics Corporation, the world’s leading provider of hair drug testing, is proud to announce it has been named “Most Innovative Drug Testing Company of the Year” by Acquisition International Magazine as part of its prestigious 2025 Global Excellence Awards. This recognition honors Psychemedics’ continued leadership in advancing the science of drug detection, including the recent launch of its Enhanced Quartile Reporting. This breakthrough analytics tool provides deeper insi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.